HOME Life Sciences Technology

Sofinnova Partners is an independent venture capital firm based in Paris. We invest in early stage companies, corporate spin-offs and turnaround situations in the technology and life sciences spaces, including cleantech:

460 companies financed in Europe since 1972
Over 1 in 5 companies financed have gone public
Over 1 in 5 companies financed have been acquired
40 jobs created per company on average between financing and exit
Revenues multiplied by 8 on average between financing and exit.

"We are transparent. The trust and confidence we have built with our entrepreneurs and our limited partners is the cornerstone for our future successes."
Monique Saulnier

Managing Partner & CFO

In Life Sciences, Sofinnova Partners focuses on ambitious projects developing new therapeutics in both biopharmaceuticals and medical devices.
Priority is given to companies that :

develop new products for unmet clinical needs and with early clinical proof of concept
address big markets: from oncology to diseases of the central nervous system, from metabolic to infectious diseases
combine entrepreneurial with pharmaceutical experience.

The disruptive technologies that Sofinnova concentrate on may lead us to deals in the cleantech field such as biofuel, green chemicals, waste management, water treatment....

In the Technology sector, Sofinnova Partners focuses on disruptive technologies and business models in areas that include:

telecommunication/consumer electronics and wireless devices
wireless internet, internet
other technologies and markets including energy or photonics.

The disruptive technologies that we concentrate on may lead us to deals in the cleantech sector including alternative energy, storage, efficiency...

The News

Entrepreneur Section

Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com

Sofinnova

Searches hundreds of airline companies, travel agents, and hotel resellers in real time to provide best deals with utmost accuracy.
Sprice
Alosteric modulation of m-gluR receptors is on the forefront of innovations for new CNS drugs and specifically for anxiety, depression and schizophrénia.
Addex Pharmaceuticals
Producing glyconjugates in a single step is the challenge GlycoVaxyn is facing in order to get vaccins cheaper and easier to produce.
GlycoVaxyn
Add finally the combined autofocus, zoom and image optical stabilization solution to mobile phones, webcams and barcode readers, with the only « no-moving parts » lenses based on electrowetting technology.
Varioptic
Myriad is a global leader in mobile technology with software in over 2 billion phones. Our deep expertise and broad portfolio help leading device manufacturers and mobile operators deliver amazing experiences on mass market phones.
Myriad
PC30’s mission is to help at home all that is related to digital installation and maintenance. PC30 operates a strong network of 70 agencies all over France and manages 70 000 on field interventions each month. PC30 is now expanding its activities in Italy and Belgium.
PC30
Facilitates transactions, including payment, access control, file transfer, transport… IC has the leading and complete Near Field Communication solution.
Inside Contactless
Boosts the consumption and stickiness of mobile content and applications, with a single thin client rich server solution for video streaming, mobile TV, web-access, music and rich content screen…
Streamezzo
Adds convenience and enables one touch security on mobile phone and PC, with a new fingerprint hardware and software solution.
Upek
Percutaneous aortic valve replacement is a technology breakthrough for patients who will need only a few days of hospitalisation.
Corevalve
Taptu is an incredibly efficient mobile search service totally dedicated to wireless handset. Taptu delivers fast content with an innovative and friendly user interface.
Taptu
Solves the energy problem in mobile phones, cameras, hearing aids… with a new rechargeable Zn-Air battery with more than 2 times energy density compared to today Li based batteries.
Revolt
Solves the issue of the simple access to PC files on TV, with a fully featured media center solution, at a low street price and with an easy-to-use software and remote interface.
Wyplay
Nanobodies®, derived from natural single chain antibodies in Camelides, will be the next generation therapeutic antibodies. The anti-TNFalpha is the first under clinical investigation.
Ablynx
Diallertest® Milk is becoming the standard of diagnostic for young children milk allergy. DBV is developping this VIASKIN® technology to diagnose and treat other allergies like peanuts…
DBV Technologies